Cargando…
Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
Background: Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). Currently, the timing of thoracic radiation therapy (TRT) remains the subject of randomised trials and meta-analyses. To investigate a correlation between CRT schedule parameters and ov...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118664/ https://www.ncbi.nlm.nih.gov/pubmed/27877216 http://dx.doi.org/10.7150/jca.16741 |
_version_ | 1782468967669956608 |
---|---|
author | Manapov, Farkhad Eze, Chukwuka Niyazi, Maximilian Roengvoraphoj, Olarn Li, Minglun Hegemann, Nina-Sophie Hildebrandt, Guido Fietkau, Rainer Belka, Claus |
author_facet | Manapov, Farkhad Eze, Chukwuka Niyazi, Maximilian Roengvoraphoj, Olarn Li, Minglun Hegemann, Nina-Sophie Hildebrandt, Guido Fietkau, Rainer Belka, Claus |
author_sort | Manapov, Farkhad |
collection | PubMed |
description | Background: Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). Currently, the timing of thoracic radiation therapy (TRT) remains the subject of randomised trials and meta-analyses. To investigate a correlation between CRT schedule parameters and overall survival (OS) in a real-life patient cohort, a temporal analysis was performed. Methods: 182 LD SCLC patients successfully treated with definitive CRT were retrospectively reviewed. TRT was applied concurrently or sequentially. Impact of the treatment mode and interval of simultaneous treatment (IST) (an interval in days when chemotherapy and TRT were applied simultaneously, including time between chemotherapy cycles and weekends) on OS was analysed. Results: 71 (39%) patients were treated with concurrent and 111 (61%) with sequential CRT. Median overall survival (MS) for the entire cohort was 534 days (95%CI 461 - 607) without any significant difference between the concurrent and sequential groups (589: 95%CI 358 - 820 vs. 533: 95%CI 446 - 620 days, p=0.746, log-rank test). IST was 0 days in 111 (61%) patients treated sequentially whereas in the concurrent group, 20 (11%) and 51 (28%) patients showed an IST < 35 and > 35 days, respectively. Patients with IST > 0 and < 35 days demonstrated a trend to improved overall survival (MS: IST 0 vs. > 35 vs. < 35 was 533 vs. 448 vs. 1169 days, p=0.109, log-rank test). When patients treated with sequential CRT (IST 0) were excluded from the analysis, statistical difference in overall survival according to the IST subgroups (IST > 35 vs. < 35) became significant (p=0.021, log-rank test). On multivariate analysis of patients treated with concurrent CRT, IST > 0 and < 35 days remained a variable that significantly correlated with better overall survival (p=0.039, HR 0.38). Conclusion: In this real-life LD SCLC patient cohort, improved overall survival was achieved in patients treated with CRT schedule according to the IST > 0 and < 35-day concept. By exceeding the 35-day interval, we have seen deterioration in survival. |
format | Online Article Text |
id | pubmed-5118664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-51186642016-11-22 Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort Manapov, Farkhad Eze, Chukwuka Niyazi, Maximilian Roengvoraphoj, Olarn Li, Minglun Hegemann, Nina-Sophie Hildebrandt, Guido Fietkau, Rainer Belka, Claus J Cancer Research Paper Background: Chemoradiotherapy (CRT) is a treatment standard in limited disease (LD) small cell lung cancer (SCLC). Currently, the timing of thoracic radiation therapy (TRT) remains the subject of randomised trials and meta-analyses. To investigate a correlation between CRT schedule parameters and overall survival (OS) in a real-life patient cohort, a temporal analysis was performed. Methods: 182 LD SCLC patients successfully treated with definitive CRT were retrospectively reviewed. TRT was applied concurrently or sequentially. Impact of the treatment mode and interval of simultaneous treatment (IST) (an interval in days when chemotherapy and TRT were applied simultaneously, including time between chemotherapy cycles and weekends) on OS was analysed. Results: 71 (39%) patients were treated with concurrent and 111 (61%) with sequential CRT. Median overall survival (MS) for the entire cohort was 534 days (95%CI 461 - 607) without any significant difference between the concurrent and sequential groups (589: 95%CI 358 - 820 vs. 533: 95%CI 446 - 620 days, p=0.746, log-rank test). IST was 0 days in 111 (61%) patients treated sequentially whereas in the concurrent group, 20 (11%) and 51 (28%) patients showed an IST < 35 and > 35 days, respectively. Patients with IST > 0 and < 35 days demonstrated a trend to improved overall survival (MS: IST 0 vs. > 35 vs. < 35 was 533 vs. 448 vs. 1169 days, p=0.109, log-rank test). When patients treated with sequential CRT (IST 0) were excluded from the analysis, statistical difference in overall survival according to the IST subgroups (IST > 35 vs. < 35) became significant (p=0.021, log-rank test). On multivariate analysis of patients treated with concurrent CRT, IST > 0 and < 35 days remained a variable that significantly correlated with better overall survival (p=0.039, HR 0.38). Conclusion: In this real-life LD SCLC patient cohort, improved overall survival was achieved in patients treated with CRT schedule according to the IST > 0 and < 35-day concept. By exceeding the 35-day interval, we have seen deterioration in survival. Ivyspring International Publisher 2016-10-17 /pmc/articles/PMC5118664/ /pubmed/27877216 http://dx.doi.org/10.7150/jca.16741 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Manapov, Farkhad Eze, Chukwuka Niyazi, Maximilian Roengvoraphoj, Olarn Li, Minglun Hegemann, Nina-Sophie Hildebrandt, Guido Fietkau, Rainer Belka, Claus Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort |
title | Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort |
title_full | Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort |
title_fullStr | Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort |
title_full_unstemmed | Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort |
title_short | Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort |
title_sort | investigating a correlation between chemoradiotherapy schedule parameters and overall survival in a real-life ld sclc patient cohort |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118664/ https://www.ncbi.nlm.nih.gov/pubmed/27877216 http://dx.doi.org/10.7150/jca.16741 |
work_keys_str_mv | AT manapovfarkhad investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT ezechukwuka investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT niyazimaximilian investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT roengvoraphojolarn investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT liminglun investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT hegemannninasophie investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT hildebrandtguido investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT fietkaurainer investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort AT belkaclaus investigatingacorrelationbetweenchemoradiotherapyscheduleparametersandoverallsurvivalinareallifeldsclcpatientcohort |